Conformal Medical

Executive Summary

Conformal Medical, now a wholly owned subsidiary of W. L. Gore & Associates (acquired February 2026), is a medical device company focused on stroke prevention in patients with non-valvular atrial fibrillation. Its lead product, the CLAAS® AcuFORM™ System, is a next-generation left atrial appendage occlusion (LAAO) device designed to simplify implantation through a conformable, single-lobe design that adapts to varying anatomy. The acquisition by Gore, a global leader in medical devices, provides Conformal with substantial resources for commercialization, regulatory expertise, and distribution infrastructure. With the CLAAS AcuFORM System poised to compete in the growing LAAO market (expected to exceed $2B by 2030), the company benefits from strong clinical evidence and Gore's established relationships with interventional cardiologists. The system's key differentiator is its simplified delivery and deployment, aiming to reduce procedure time and improve safety. Following acquisition, Conformal is expected to accelerate global market penetration, with a focus on expanding indications and securing regulatory approvals in major markets. The combined entity is well-positioned to capture market share from established players like Boston Scientific's Watchman and Abbott's Amulet.

Upcoming Catalysts (preview)

• Q3 2026FDA approval/clearance for CLAAS AcuFORM System90% success
• Q4 2026First commercial implants in the US post-acquisition80% success
• Q2 2026Publication of pivotal trial results in peer-reviewed journal85% success